Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3b trial of oral edaravone dosing regimens in ALS
jRCT2031200301Phase 3Completed
- Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Start
- Jan 2021
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in amyotrophic lateral sclerosis (ALS) comparing Once-daily oral edaravone with On/off oral edaravone plus placebo (2 arms). Primary endpoint: Change in ALSFRS-R score from baseline to Week 48. Started Jan 2021; status: completed.
02
Drugs
edaravone
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on jRCT2031200301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200301.